OverviewSuggest Edit

Shockwave Medical is a company developing interventional therapy for calcified cardiovascular disease. It provides the Lithoplasty balloon dilatation catheters. The company also offers intravascular lithotripsy, a novel treatment option that allows calcium modification.
TypePublic
Founded2009
HQFremont, CA, US
Websiteshockwavemedical.com
Employee Ratings3.6

Latest Updates

Employees (est.) (Dec 2018)162
Revenue (FY, 2019)$42.9 M(+251%)
Share Price (Jan 2021)$118.6 (-1%)
Cybersecurity ratingBMore

Key People/Management at Shockwave Medical

Doug Godshall

Doug Godshall

President, CEO & Director
Rob Williamson

Rob Williamson

VP of Sales
Dan Puckett

Dan Puckett

Chief Financial Officer
Isaac Zacharias

Isaac Zacharias

Chief Commercial Officer
Keith D. Dawkins

Keith D. Dawkins

Chief Medical Officer
Hajime Tada

Hajime Tada

General Counsel
Show more

Shockwave Medical Office Locations

Shockwave Medical has offices in Fremont, Philadelphia, Santa Clara and Kleve
Fremont, CA, US (HQ)
Warm Springs Blvd
Philadelphia, PA, US
Philadelphia, PA, USA
Santa Clara, CA, US
5403 Betsy Ross Dr
Kleve, DE
Siemensstraße 31
Show all (4)

Shockwave Medical Financials and Metrics

Shockwave Medical Revenue

Embed Graph
View revenue for all periods
Shockwave Medical's revenue was reported to be $42.93 m in FY, 2019
USD

Revenue (Q2, 2020)

10.3m

Gross profit (Q2, 2020)

6.7m

Gross profit margin (Q2, 2020), %

65.1%

Net income (Q2, 2020)

(18.1m)

EBIT (Q2, 2020)

(18.0m)

Market capitalization (8-Jan-2021)

4.1b

Closing stock price (8-Jan-2021)

118.6

Cash (30-Jun-2020)

218.3m

EV

3.9b
Shockwave Medical's current market capitalization is $4.1 b.
Annual
USDFY, 2017FY, 2018FY, 2019

Revenue

1.7m12.3m42.9m

Revenue growth, %

613%

Cost of goods sold

2.8m7.3m17.2m

Gross profit

(1.1m)5.0m25.8m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

7.3m10.0m11.3m15.2m10.3m

Cost of goods sold

3.1m4.1m4.4m5.7m3.6m

Gross profit

4.2m5.9m6.9m9.5m6.7m

Gross profit Margin, %

58%59%61%63%65%
Annual
USDFY, 2017FY, 2018FY, 2019

Cash

51.9m39.6m139.0m

Accounts Receivable

639.0k2.9m7.4m

Prepaid Expenses

968.0k1.1m1.9m

Inventories

2.5m5.1m12.1m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

138.1m41.9m39.5m123.1m218.3m

Accounts Receivable

3.9m5.2m5.6m7.8m6.4m

Prepaid Expenses

2.5m2.0m2.2m3.5m3.1m

Inventories

7.0m8.3m9.2m15.9m23.4m
Annual
USDFY, 2017FY, 2018FY, 2019

Net Income

(30.6m)(41.1m)(51.1m)

Depreciation and Amortization

468.0k700.0k1.3m

Inventories

(1.9m)(2.6m)(6.8m)

Accounts Payable

249.0k360.0k1.3m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(12.8m)(23.4m)(36.4m)(18.8m)(36.9m)

Depreciation and Amortization

255.0k516.0k854.0k426.0k877.0k

Inventories

(1.9m)(3.2m)(4.1m)(3.8m)(11.0m)

Accounts Payable

369.0k713.0k884.0k(542.0k)(282.0k)
USDFY, 2017

Financial Leverage

1.1 x
Show all financial metrics

Shockwave Medical Operating Metrics

Feb, 2019

Patients Tested to Date

179
Show all operating metrics

Shockwave Medical Acquisitions / Subsidiaries

Company NameDateDeal Size
ShockWave Medical GmbH

Shockwave Medical Revenue Breakdown

Embed Graph

Shockwave Medical revenue breakdown by geographic segment: 57.3% from United States, 11.4% from Germany, 28.7% from Rest of Europe and 2.7% from Other

Shockwave Medical Cybersecurity Score

Cybersecurity ratingPremium dataset

B

86/100

SecurityScorecard logo

Shockwave Medical Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

CSRHub logo

Shockwave Medical Online and Social Media Presence

Embed Graph

Shockwave Medical News and Updates

Shockwave Medical to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

SANTA CLARA, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that it will be participating in the Piper Sandler 32nd Annual Virtual H…

Shockwave Medical to Participate in the 13th Annual Canaccord Genuity Medical Technologies & Diagnostics Forum

SANTA CLARA, Calif., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced the company will participate in a fireside chat wi…

Shockwave Medical to Participate in Upcoming Investor Conferences

SANTA CLARA, Calif. , Aug. 21, 2019 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced the company will be participating in two upcoming…

Shockwave Medical Blogs

IVL in Real-World European Population: Q&A with Dr. Sandeep Basavarajaiah & Dr. Alfonso Ielasi

Dr. Sandeep Basavarajaiah, consultant cardiologist at Heartlands Hospital in Birmingham, UK, and other leading UK and Italian cardiologists published their initial real-world experience with Intravascular Lithotripsy (IVL) in a real-world population, in Catheter Cardiovasc Interv: “Intra…

PCR London Valve: Simplify TAVI – Keep it Femoral

At the recent PCR Valves eCourse (aka London Valves), an esteemed faculty reported on the use of IVL- facilitated TAVI. Profs./Drs. Carlo Di Mario, Ole De Backer, Joachim Schofer, Constantin von zur Mühlen used published data and case experiences to illustrate the advantages of using IVL…

CAD III ShockTalk: A Discussion about the Data’s Significance

At TCT Connect, investigators presented the 30-day primary endpoint analysis of the Disrupt CAD III study, the largest and most rigorous coronary IVL study to date.

DISRUPT PAD III: Superior in Prep

In life, and when treating patients, we all prefer things to be less complicated.  Unfortunately, treating peripheral vascular calcification is typically associated with suboptimal vessel expansion and an increased risk of complications.

See what Superiority looks like… The First Level 1 Evidence in Calcified PAD

In DISRUPT PAD III, we included the complex, torturous, calcified lesions and risky patients that other studies avoid.  Review the results for yourself and see what superior looks like.

Clinical Corner with Dr. Keith Dawkins: IVL-Induced Ventricular Capture

Perspective on IVL-Induced Ventricular Capture from Keith D. Dawkins, M.D., Chief Medical Officer, Shockwave Medical, Inc.:
Show more

Shockwave Medical Frequently Asked Questions

  • When was Shockwave Medical founded?

    Shockwave Medical was founded in 2009.

  • Who are Shockwave Medical key executives?

    Shockwave Medical's key executives are Doug Godshall, Rob Williamson and Dan Puckett.

  • How many employees does Shockwave Medical have?

    Shockwave Medical has 162 employees.

  • What is Shockwave Medical revenue?

    Latest Shockwave Medical annual revenue is $42.9 m.

  • What is Shockwave Medical revenue per employee?

    Latest Shockwave Medical revenue per employee is $265 k.

  • Who are Shockwave Medical competitors?

    Competitors of Shockwave Medical include Metric Medical Devices, Spineway and Theraclion.

  • Where is Shockwave Medical headquarters?

    Shockwave Medical headquarters is located at Warm Springs Blvd, Fremont.

  • Where are Shockwave Medical offices?

    Shockwave Medical has offices in Fremont, Philadelphia, Santa Clara and Kleve.

  • How many offices does Shockwave Medical have?

    Shockwave Medical has 4 offices.